Meeting
2020 ASCO Virtual Scientific Program
Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.
Authors
Mridula Krishnan
University of Nebraska Medical Center, Omaha, NE
Mridula Krishnan , Benjamin A. Teply , Fang Yu , Robin High
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
End-of-Life Care
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12028)
DOI
10.1200/JCO.2020.38.15_suppl.12028
Abstract #
12028
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.
First Author: Vaia Florou
Poster
2023 ASCO Annual Meeting
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
First Author: Tämer El Saadany
Poster
2022 ASCO Annual Meeting
Predictors of response to immune checkpoint inhibitors (ICI) rechallenge post-disease progression in solid tumors: A systematic review and meta-analyses.
First Author: Hassan Mohammed Abushukair
Poster
2022 ASCO Annual Meeting
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in solid tumors: Data-mining of 1,382 electronic patient records.
First Author: Mathilde Beaufils